The Workhorse — Industrial & Warehouse Robotics
The robotics revenue that's actually happening today, while humanoids are still in beta.
While the humanoid story dominates X/Twitter, the boring industrial robotics revenue is shipping at billions of dollars per year, right now . Three subdomains have real cashflow and real moats: warehouse automation (Symbotic powering Walmart, AutoStore in Europe), surgical robotics (Intuitive Surgical with the da Vinci platform — 99% gross margins on a $2M machine), and semiconductor test & cobots (Teradyne + its Universal Robots cobot arm subsidiary). These are not "futures." They're "compounders that also have humanoid optionality."
If you don't believe humanoids ship at scale in this decade, these are the names you still want to own — they're getting the robotics multiple even if Optimus disappoints. And they're already profitable.
3 names on the watchlist
End-to-end warehouse automation — Walmart's exclusive backbone
Builds the entire robotic guts of a modern warehouse — autonomous bots that move pallets and cases at high speed, racking, software. Walmart has committed to deploying Symbotic in all 42 of its US regional distribution centers — a $11B+ contract. Also has GreenBox, a joint venture with SoftBank to operate as a service. $22.4B backlog as of Q2 2026.
da Vinci surgical robotics — the platform monopoly with razor-blade economics
The da Vinci robotic surgery platform — sold to hospitals at ~$2M per system, then bills $1,500+ of recurring "instruments & accessories" revenue every single time a surgeon uses it. ~9,500 systems installed globally; ~3M procedures per year and growing 15-20%. Razor-and-blades economics with no real competitor . The 2024 da Vinci 5 launch refreshes the platform.
North American factory automation incumbent — reshoring pure-play
Sells programmable logic controllers (PLCs), drives, motion control, and automation software to North American manufacturers. CHIPS Act fab construction (Intel Ohio, TSMC Arizona, Samsung Texas), Inflation Reduction Act EV factories, and pharma capacity expansion all flow through Rockwell. Lower beta than humanoid plays but real, durable demand. Trades at fair multiple given the cycle stage.